GSK GSK plc IFRS Annual reports only
Pharmaceutical Preparations · NYSE · SEC CIK 1131399 · Reporting currency GBP
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: GBP | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 32.67B | 31.38B | 30.33B | 29.32B | 24.70B |
| Cost of revenue | 9.02B | 9.05B | 8.56B | 9.55B | 8.16B |
| Gross profit | 23.65B | 22.33B | 21.76B | 19.77B | 16.53B |
| R&D expense | 7.53B | 6.40B | 6.22B | 5.49B | 5.02B |
| SG&A expense | 9.09B | 11.02B | 9.38B | 8.37B | 7.07B |
| Operating income | 7.93B | 4.02B | 6.75B | 6.43B | 4.36B |
| Interest expense | 701.00M | 669.00M | 792.00M | 879.00M | 769.00M |
| Pretax income | 7.40B | 3.48B | 6.06B | 5.63B | 3.60B |
| Income tax | 1.11B | 526.00M | 756.00M | 707.00M | 83.00M |
| Net income | 5.72B | 2.58B | 4.93B | 14.96B | 4.38B |
| EBITDA | 10.25B | 6.57B | 9.04B | 8.58B | 6.48B |
| EPS (basic) | 1.41 | 0.63 | 1.22 | 3.71 | 1.10 |
| EPS (diluted) | 1.39 | 0.62 | 1.20 | 3.66 | 1.08 |
| Weighted avg. shares (diluted) | 4.12B | 4.14B | 4.11B | 4.08B | 4.05B |
| Balance sheet | |||||
| Cash & equivalents | 3.40B | 3.87B | 2.94B | 3.72B | 4.27B |
| Receivables | 7.47B | 6.84B | 7.38B | 7.05B | 7.86B |
| Inventory | 5.92B | 5.67B | 5.50B | 5.15B | 5.78B |
| Current assets | 17.51B | 17.00B | 18.64B | 20.77B | 18.67B |
| PP&E, netmay include right-of-use assets (IFRS) | 9.32B | 9.23B | 9.02B | 8.93B | 9.93B |
| Goodwill | 7.02B | 6.98B | 6.81B | 7.05B | 10.55B |
| Intangibles | 16.75B | 15.52B | 14.77B | 14.32B | 30.08B |
| Total assets | 61.12B | 59.46B | 59.01B | 60.15B | 79.10B |
| Current liabilities | 21.39B | 21.70B | 21.07B | 22.81B | 23.67B |
| Short-term debt | 3.01B | 2.35B | 2.81B | 3.95B | 3.60B |
| Long-term debt | 14.71B | 14.64B | 15.21B | 17.04B | 20.57B |
| Total debt | 17.72B | 16.99B | 18.02B | 20.99B | 24.17B |
| Total liabilities | 45.16B | 46.38B | 46.21B | 50.05B | 57.76B |
| Shareholders' equity | 16.38B | 13.67B | 13.35B | 10.60B | 15.05B |
| Net debt | 14.32B | 13.12B | 15.08B | 17.26B | 19.90B |
| Cash flow statement | |||||
| Operating cash flow | 7.74B | 6.55B | 6.77B | 7.40B | 7.95B |
| Capital expenditure | 1.35B | 1.40B | 1.31B | 1.14B | 950.00M |
| Free cash flow | 6.39B | 5.16B | 5.45B | 6.26B | 7.00B |
| Investing cash flow | -4.23B | -1.23B | -1.59B | -8.77B | -1.78B |
| Financing cash flow | -3.69B | -4.73B | -5.64B | 823.00M | -7.59B |
| Depreciation & amortization | 2.31B | 2.55B | 2.29B | 2.15B | 2.12B |
| Stock-based compensation | 374.00M | 344.00M | 307.00M | 346.00M | 343.00M |
| Dividends paid | 2.56B | 2.44B | 2.25B | 3.47B | 4.00B |
| Share buybacks | 1.38B | 0 | 0 | — | — |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· Amounts are in the company's reporting currency, GBP, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.